These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 26823276

  • 1. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K, Smith L, Kuliczkowski K, Korth-Bradley J, You CW, Fuiman J, Zupančić-Šalek S, Abdul Karim F, Rendo P.
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [Abstract] [Full Text] [Related]

  • 2. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P.
    Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
    [Abstract] [Full Text] [Related]

  • 3. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
    Negrier C, Young G, Abdul Karim F, Collins PW, Hanabusa H, Colberg T, Goldman B, Walsh CE, paradigm™ 2 and 4 Investigators.
    Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
    [Abstract] [Full Text] [Related]

  • 4. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL.
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM, Rendo P, Smith L, Altisent C.
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G.
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE.
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [Abstract] [Full Text] [Related]

  • 8. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
    Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA.
    Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E.
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [Abstract] [Full Text] [Related]

  • 10. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E, Keeling D, Makris M, Tagliaferri A, Male C, Mauser-Bunschoten EP, Musso R, Roca CA, Hassoun A, Kollmer C, Charnigo R, Baumann J, Rendo P.
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [Abstract] [Full Text] [Related]

  • 11. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
    Yang R, Wu R, Sun J, Sun F, Rupon J, Huard F, Korth-Bradley JM, Xu L, Luo B, Liu YC, Rendo P.
    Medicine (Baltimore); 2021 May 28; 100(21):e26077. PubMed ID: 34032739
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Ghandehari H, Chapman M, Fritsch S, Wong WY, Pavlova BG, Abbuehl BE.
    Haemophilia; 2014 Sep 28; 20(5):651-8. PubMed ID: 24697870
    [Abstract] [Full Text] [Related]

  • 13. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, Maro G, Malcangi G.
    Adv Ther; 2020 Jun 28; 37(6):2988-2998. PubMed ID: 32333327
    [Abstract] [Full Text] [Related]

  • 14. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, Diao L, Ramirez-Santiago A, Pierce GF, Allen G.
    Lancet Haematol; 2017 Feb 28; 4(2):e75-e82. PubMed ID: 28159192
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.
    Haemophilia; 2017 Jul 28; 23(4):547-555. PubMed ID: 28233381
    [Abstract] [Full Text] [Related]

  • 16. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañes M, Paez A.
    Haemophilia; 2010 Mar 28; 16(2):240-6. PubMed ID: 20015218
    [Abstract] [Full Text] [Related]

  • 17. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.
    Rendo P, Smith L, Lee HY, Shafer F.
    Blood Coagul Fibrinolysis; 2015 Dec 28; 26(8):912-8. PubMed ID: 26196195
    [Abstract] [Full Text] [Related]

  • 18. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.
    Fukutake K, Taki M, Matsushita T, Sakai M, Takata A, Yamaguchi H, Karumori T.
    Haemophilia; 2019 Jul 28; 25(4):e247-e256. PubMed ID: 31168882
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
    Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B.
    Thromb Haemost; 2017 Feb 28; 117(3):508-518. PubMed ID: 28004057
    [Abstract] [Full Text] [Related]

  • 20. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.
    Haemophilia; 2016 May 28; 22(3):374-80. PubMed ID: 26582282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.